Top

Journal of Diabetes & Metabolic Disorders

Published in:

01-12-2020 | Insulins | Research article

Polydatin-loaded chitosan nanoparticles ameliorates early diabetic nephropathy by attenuating oxidative stress and inflammatory responses in streptozotocin-induced diabetic rat

Author: Abeer M. Abd El-Hameed

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Abstract

In various developed countries, diabetic nephropathy (DN) is the principal cause of end-stage kidney disease and a main reason of injury and mortality in individuals with renal morbidity worldwide. Polydatin (POL) has been evaluated as a potential antioxidant, anti-inflammatory and a nephroprotective agent. In spite of this, the possible benefits and protective effects of POL on early diabetic nephropathy are not quite clarified. For the effective clearance from the body besides safe drug delivery, biodegradable nanoparticles have interesting attraction. This work was designed to evaluate the positive effect and possible mechanisms of Polydatin-loaded Chitosan-Nanoparticles (POL-NPs) on early DN in streptozotocin–induced diabetic rats. Followed the induction of diabetes, rats classified into four groups, diabetic control and diabetic rats treated daily and orally with; POL, Polydatin-loaded chitosan-Nanoparticles (POL-NPs), plus normal control rats. Our findings showed that diabetic group presented a significant high level of the blood glucose, blood glycosylated hemoglobin (HbA1c), serum insulin, renal function related parameters, renal Advanced glycation-end products (AGEs) and lipid peroxidation level compared to normal control rats, while serum albumin level and the activities of renal antioxidant enzymes were significantly decreased. Moreover, in the kidney of diabetic rat mRNA expression of nuclear factor-kappa B (NF-κB) and cyclooxygenase-2 (Cox-2) were up-regulated. Besides, increase in serum levels of pro-inflammatory cytokines (TNF-α, IL-6 and IL-18) and decrease in anti-inflammatory cytokine (IL-10). POL and POL-NPs supplementation were significantly attenuate the above-mention results and returned the normal equilibrium between pro- and anti-inflammatory cytokines. In conclusion, POL and POL-NPs have antidiabetic effect, suppresses oxidative stress and mitigates renal inflammation through inhibition of NF-κB in diabetic kidney in early progressive DN.

Mahmoud AM, Mohamed B, Ashour A, Abdel-Moneim OMA. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complications. 2012;26(6):483–90.PubMed

Huang QH, Xu LQ, Liu YH, Wu JZ, Wu X, Lai XP, et al. Polydatin protects rat liver against ethanol-induced injury: involvement of CYP2E1/ROS/Nrf2 and TLR4/NF-κB p65 pathway. Evidence-Based Complement Altern Med. 2017;2017:14. https://doi.org/10.1155/2017/7953850.

Park CH, Noh JS, Yamabe N, Kang KS, Tanaka T, Yokozawa T. Beneficial effect of 7-O-galloyl-d-sedoheptulose on oxidative stress and hepatic and renal changes in type 2 diabetic db/db mice. Eur J Pharmacol. 2010;640(1–3):233–42.PubMed

Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur J Pharmacol. 2016;791:8–24.PubMed

Zhang H, Zhao T, Gong Y, Dong X, Zhang W, Sun S, et al. Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics. J Ethnopharmacol [Internet]. 2014;151(1):556–64. https://doi.org/10.1016/j.jep.2013.11.020.CrossRefPubMed

Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54(6):1615–25.PubMed

Wan TT, Li XF, Sun YM, Li YB, Su Y. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Biomed Pharmacother. 2015;74:145–7.PubMed

Fang J, Luo L, Ke Z, Liu C, Yin L, Yao Y, et al. Polydatin protects against acute cholestatic liver injury in mice via the inhibition of oxidative stress and endoplasmic reticulum stress. J Funct Foods. 2019;55:175–83.

Du QH, Peng C, Zhang H. Polydatin. A review of pharmacology and pharmacokinetics. Pharm Biol. 2013;51(11):1347–54.PubMed

10.

Chen C, Huang K, Hao J, Huang J, Yang Z, Xiong F, et al. Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway. Mol Cell Endocrinol [Internet]. 2016;427:45–56. https://doi.org/10.1016/j.mce.2016.03.003.

11.

Xie X, Peng J, Huang K, Huang J, Shen X, Liu P, et al. Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells. Mol Cell Endocrinol. 2012;362(1–2):183–93.PubMed

12.

Cheng W, Li X, Zhang C, Chen W, Yuan H, Xu S. International journal of drug development preparation and in vivo-in vitro evaluation of polydatin-phospholipid complex with improved dissolution and bioavailability. Int J Drug Dev Res. 2017;9(1):39–43.

13.

Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012;158(2):182–93.PubMed

14.

Nagpal K, Singh SK, Mishra DN. Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety. Int J Biol Macromol. 2013;59:72–83.PubMed

15.

Abdel-Moneim A, El-Shahawy A, Yousef AI, Abd El-Twab SM, Elden ZE, Taha M. Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches. Int J Biol Macromol [Internet]. 2020;154:1496–504. https://doi.org/10.1016/j.ijbiomac.2019.11.031.CrossRefPubMed

16.

Xiao Z, Wang Y long, Yue Y, Zhang Y, tang, Chen C ping, Wan L sheng, et al. Preventive effects of polysaccharides from Liriope spicata var. prolifera on diabetic nephropathy in rats. Int J Biol Macromol [Internet]. 2013;61:114–20. https://doi.org/10.1016/j.ijbiomac.2013.06.047.

17.

Soufi FG, Mohammad-nejad D, Ahmadieh H. Resveratrol improves diabetic retinopathy possibly through oxidative stress - Nuclear factor κB - Apoptosis pathway. Pharmacol Reports. 2012;64(6):1505–14.

18.

Sugano M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, et al. High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: A new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis. 2006;16(7):477–84.PubMed

19.

Meng G, Zhu H, Yang S, Wu F, Zheng H, Chen EE, et al. Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydr Polym [Internet]. 2011;84(1):180–5. https://doi.org/10.1016/j.carbpol.2010.11.016.

20.

Khanra R, Bhattacharjee N, Dua TK, Nandy A, Saha A, Kalita J, et al. Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats. Biomed Pharmacother [Internet]. 2017;94:726–41. https://doi.org/10.1016/j.biopha.2017.07.112.

21.

Hosni AA, Abdel-Moneim AA, Abdel-Reheim ES, Mohamed SM, Helmy H. Cinnamaldehyde potentially attenuates gestational hyperglycemia in rats through modulation of PPARγ, proinflammatory cytokines and oxidative stress. Biomed Pharmacother. 2017;88:52–60.PubMed

22.

Abdel-Mone A, Hosni A, Abdel-Rehe ES, Ismail A. Role of PPARγ/Anti-inflammatory Axis in the Protective Effect of Ellagic Acid Against FSD/STZ-induced Gestational Diabetes in Rats. Asian J Biol Sci. 2020;13(2):228–36.

23.

Bakry LN, El-Hameed AMA, El-Twab SMA, Ahmed OM, A-MA. The preventive effects of Cynara scolymus leaf and flower extracts on diethylnitrosamine/ acetylaminoflourene induced nephrotoxicity in male wistar rats. Adv Anim Vet Sci. 2020;8(2):74–81.

24.

Khanra R, Dewanjee S, K Dua T, Sahu R, Gangopadhyay M, DeFeo V, et al. Abroma augusta L. (Malvaceae) leaf extract attenuates diabetes induced nephropathy and cardiomyopathy via inhibition of oxidative stress and inflammatory response. J Transl Med. 2015;13(1):6.

25.

Wang X, Zhang X, He Y, Yang G, Lu J, Li J, et al. Protective effects of tranilast on diabetic nephropathy in rats. Med J Wuhan Univ. 2013;34(1):42–5.

26.

El-hameed AMA, Eskandrani AA, Elroby FA. Assessment of the ameliorative effect of Hypericum perforatum on olanzapine-induced hepatic oxidative stress and metabolic abnormalities in experimental male albino rats. 2020. https://doi.org/10.1080/16583655.2020.1834757.

27.

Li T, Cai S, Zeng Z, Zhang J, Gao Y, Wang X, et al. Protective effect of polydatin against bum-induced lung injury in rats. Respir Care. 2014;59(9):1412–21.PubMed

28.

Sen S, Kar M, Roy A, Chakraborti AS. Effect of nonenzymatic glycation on functional and structural properties of hemoglobin. Biophys Chem. 2005;113(3):289–98.PubMed

29.

Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol. 2005;16(4):257–74.PubMed

30.

Abouzed TK, del Mar Contreras, Sadek M, Shukry KM, Abdelhady MH, Gouda D. WM, et al. Red onion scales ameliorated streptozotocin-induced diabetes and diabetic nephropathy in Wistar rats in relation to their metabolite fingerprint. Diabetes Res Clin Pract. 2018;140:253–64.

31.

Achilles CM, Reynolds JS, Achilles SH. Problem analysis [Internet]. Problem analysis. 2014. https://doi.org/10.1016/j.biochi.2015.03.025%0A, https://doi.org/10.1038/nature10402%0A, https://doi.org/10.1038/nature21059%0A, https://doi.org/10.1038/nrmicro2577%0A, http://journal.stainkudus.ac.id/index.php/equilibrium/article/view/1268/1127%0A.

32.

Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol - Ren Physiol. 2005;289:F645-59.

33.

Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003;14(SUPPL. 3):S254-8.PubMed

34.

Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, et al. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1383–95.PubMed

35.

Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis pre- dominantly through transforming growth factor beta-independent pathway. J Pathol. 2004;165:2033–43.

36.

Chen L, Lan Z, Lin Q, Mi X, He Y, Wei L, et al. Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food Chem Toxicol [Internet]. 2013;52:28–35. https://doi.org/10.1016/j.fct.2012.10.037.CrossRefPubMed

37.

Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–33.PubMed

38.

Jakuš V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res. 2004;53(2):131–42.PubMed

39.

Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29(SUPPL.):67–72.

40.

Zhao-Sheng H, Zong-Wei W, Ming-Ping L, Qiao-Mei L, Qing-Guang W. Protective effects of polydatin on CCl4-induced injury of primary cultured rat hepatocytec. Chinese Pharmacol Bull. 1998;14(6):543–5.

41.

Zhang H, Yu CH, Jiang YP, Peng C, He K, Tang JY, et al. Protective effects of polydatin from polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. PLoS One. 2012;7(9):e46574.PubMedPubMedCentral

42.

Miao Q, Wang S, Miao S, Wang J, Xie Y, Yang Q. Cardioprotective effect of polydatin against ischemia/reperfusion injury: Roles of protein kinase C and mito K ATP activation. Phytomedicine. 2011;19(1):8–12.PubMed

43.

Abd El-Hameed AM, Mahmoud HS. Cypermethrin induced apoptosis and testicular toxicity by upregulation of p53 in the brain and testis of male rats is alleviated by Sesame oil. J Taibah Univ Sci [Internet]. 2020;14(1):1342–9. https://doi.org/10.1080/16583655.2020.1822057.CrossRef

44.

Lenz O, Fornoni A, Ijaz A, Tejada T. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev. 2008;4(1):10–7.PubMed

45.

Balakumar P, Arora MK, Reddy J, Anand-Srivastava MB. Pathophysiology of diabetic nephropathy: Involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol. 2009;54(2):129–38.PubMed

46.

Han HJ, Min JL, Yun JL, Jang HL, Il SY, Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-κB. Am J Physiol - Ren Physiol. 2007;292(1):F373–81.

47.

Quan H, Peng X, Liu S, Bo F, Yang L, Huang Z, et al. Differentially expressed protein profile of renal tubule cell stimulated by elevated uric acid using SILAC coupled to LC-MS. Cell Physiol Biochem. 2011;27(1):91–8.PubMed

48.

Lee JI, Burckart GJ. Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol. 1998;38(11):981–93.PubMed

49.

Akarasereenont P, Bakhle YS, Thiemermann C, Vane JR. Cytokine-mediated induction of cyclo‐oxygenase‐2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Br J Pharmacol. 1995;115(3):401–8.PubMedPubMedCentral

50.

Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-κB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19(10):2505–12.PubMed

51.

Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism. 2003;52(5):605–8.PubMed

52.

Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16(3 SUPPL. 1):S78-82.PubMed

53.

Elsherbiny NM, Al-Gayyar MMH, Abd El Galil KH. Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. Life Sci [Internet]. 2015;143:8–17. https://doi.org/10.1016/j.lfs.2015.10.026.

54.

Li Y, Liu J, Liao G, Zhang J, Chen Y, Li L, et al. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int J Mol Med. 2018;41(5):2629–39.PubMedPubMedCentral

55.

Borgohain MP, Chowdhury L, Ahmed S, Bolshette N, Devasani K, Das TJ, et al. Renoprotective and antioxidative effects of methanolic Paederia foetida leaf extract on experimental diabetic nephropathy in rats. J Ethnopharmacol [Internet]. 2017;198:451–9. https://doi.org/10.1016/j.jep.2017.01.035.

56.

Day CP, Grove J, Daly AK, Stewart MW, Avery PJ, Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia. 1998;41(4):430–4.PubMed

57.

Fernández-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, et al. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes. 2000;49(3):517–20.PubMed

58.

Alarcon-Aguilar FJ, Fortis-Barrera A, Angeles-Mejia S, Banderas-Dorantes TR, Jasso-Villagomez EI, Almanza-Perez JC, et al. Anti-inflammatory and antioxidant effects of a hypoglycemic fructan fraction from Psacalium peltatum (H.B.K.) Cass. in streptozotocin-induced diabetes mice. J Ethnopharmacol. 2010;132(2):400–7.PubMed

59.

Crook M. Type 2 diabetes mellitus: A disease of the innate immune system? An update. Diabet Med. 2004;21(3):203–7.PubMed

60.

Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 2006;6(6):463–8.PubMed

61.

Nicoletti F, Conget I, Di Marco R, Speciale AM, Morinigo R, Bendtzen K, et al. Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing Type I diabetes. Diabetologia. 2001;44(3):309–11.PubMed

62.

Feghali CA, Wright TM. Introduction 3. Discussion 3.1 Cytokines involved in acute inflammation 3.1.1 Interleukin-1 3.1.2 Tumor necrosis factor 3.1.3 Interleukin-6 3.1.4 Interleukin-11 3.1.5 Interleukin-8/chemokines 3.1.6 Eotaxin 3.1.7 Interleukin-16 3.1.8 Interleukin-17 3.1.9 C. Front Biosci [Internet]. 1997;2:12–26. https://www.bioscience.org/1997/v2/d/feghali1/htmls/feghali.pdf.

63.

Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Parasitol Today. 1991;7(3):49–53.

64.

Wagener FADTG, Dekker D, Berden JH, Scharstuhl A, Van Der Vlag J. The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis. 2009;14(12):1451–8.PubMedPubMedCentral

65.

Lou T, Jiang W, Xu D, Chen T, Fu Y. Inhibitory Effects of Polydatin on Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2015;38(3):1213–20.PubMed

Title: Polydatin-loaded chitosan nanoparticles ameliorates early diabetic nephropathy by attenuating oxidative stress and inflammatory responses in streptozotocin-induced diabetic rat
Author: Abeer M. Abd El-Hameed
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Insulins
Diabetic Nephropathy
Cytokines
Insulins
Published in: Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-020-00699-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Medication non-adherence in patients with type 2 diabetes mellitus with full access to medicines

The effect of aerobic vs. resistance training on plasma homocysteine in individuals with type 2 diabetes

The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major

Mechanistic dissection of diabetic retinopathy using the protein-metabolite interactome

Effect of Curculigo pilosa supplemented diet on blood sugar, lipid metabolism, hepatic oxidative stress and carbohydrate metabolism enzymes in streptozotocin-induced diabetic rats

A systematic analysis on prevalence and sub-regional distribution of undiagnosed diabetes mellitus among adults in African countries

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage